The 4DMedical Ltd (ASX: 4DX) share price is in focus after the company posted a 21% lift in revenue to $7.1 million for FY26, with adjusted net loss improving 7% to $32.9 million.
Image source: Getty Images
What did 4DMedical report?
- Revenue from ordinary activities up 21% to $7.1 million
- Adjusted net loss down 7% to $32.9 million
- Statutory net loss expanded to $203 million (from $30.1 million a year ago), driven by significant non-cash items
- Gross margins remained above 90%
- No dividend declared or paid
- Net tangible assets per share improved to $0.17 (from negative $0.02)
What else do investors need to know?
4DMedical's underlying SaaS revenue climbed 23%, supported by strong growth from B2B hospital and radiology partners, third-party AI distributors, and global medical technology companies. The loss at the statutory level included a major non-cash impact—remeasurement of the Pro Medicus loan and associated derivative financial instrument—reflecting complex accounting treatment rather than core business cash outflows.
The company raised $233 million through share placements and finished the year with a robust $278 million in cash, positioning it well for ongoing investment and expansion. No dividends were declared for FY26.
What did 4DMedical management say?
Dr. Andreas Fouras, Managing Director and CEO, commented:
4DMedical has maintained strong momentum throughout FY26, improving our adjusted net loss result and strengthening our balance sheet so we can accelerate future growth initiatives.
What's next for 4DMedical?
Looking ahead, 4DMedical recently completed the acquisition of contextflow GmbH, an Austrian lung cancer screening technology company. The group also led a strategic investment in RevealDx, securing exclusive distribution rights for RevealAI-lung across key markets, including Europe, Australia, and New Zealand.
Management plans to continue scaling its commercial partnerships and integrating new technologies, while building a globally competitive medical imaging and AI platform.
4DMedical share price snapshot
Over the past 12 months, 4DMedical shares have risen nearly 700%, far outpacing the All Ordinaries Index (ASX: XAO).
